Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ASE Technology Holding Co., Ltd. American Depositary Shares (each representing (NY:ASX)

40.20 -1.65 (-3.94%)
Streaming Delayed Price Updated: 12:56 PM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ASE Technology Holding Co., Ltd. American Depositary Shares (each representing

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
ASE Expands its Chip Packaging and Testing Facility to Enable Next-Gen Applications
From Advanced Semiconductor Engineering, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 13, 2025 ↗
 
Via Benzinga
News headline image
Alterity Therapeutics Raises A$40.0 million in Placement
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Current Report ASE Technology ↗
Share price rose about 19% in the past year from $8.59 to $10.21, as of Friday’s market close. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Earnings Outlook For ASE Tech Holding Co ↗
 
Via Benzinga
News headline image
Life360 to Announce Q4 and Full Year 2024 Financial Results on February 27, 2025
From Life360, Inc.
Via GlobeNewswire
News headline image
Dotz Nano to Present at the Small Cap Growth Virtual Investor Conference February 6th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Trump Says Its Time For US To 'Return' To A System That Made It Rich And Powerful As The President Proposes Tariffs On Taiwan: 'Bring Production Back To Our Country' ↗
President Donald Trump's pledge to impose sweeping tariffs on imports from Taiwan is raising concerns across semiconductor and pharmaceutical industries, particularly affecting Taiwan Semiconductor... 
Via Benzinga
Topics Government World Trade
News headline image
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Baker Hughes Secures Liquefaction Equipment Order for Woodside Louisiana LNG
From Baker Hughes
Via GlobeNewswire
News headline image
ASE’s Sustainability Efforts Receive International Recognition With a Ranking on the Dow Jones Sustainability Indices for the Ninth Year in a Row
From ASE Technology Holding Co., Ltd.
Via Business Wire
News headline image
Precious Metals & Critical Materials Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Precious Metals & Critical Materials Virtual Investor Conference Agenda Announced for December 10th and 11th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
American Rare Earths to Present at the Precious Metals & Critical Materials Virtual Investor Conference December 11th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life360 Named One of the Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500™
Attributes 278% revenue growth to continued focus and execution of key strategic growth pillars 
From Life360, Inc.
Via GlobeNewswire
News headline image
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Life360 Reports Record Q3 2024 Results
From Life360, Inc.
Via GlobeNewswire
News headline image
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
ISE Labs Investment Secures the Establishment of New Site for Semiconductor Packaging and Test in Mexico
From Advanced Semiconductor Engineering, Inc.
Via Business Wire
News headline image
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron – 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
ASE “Guardians of the Sea” Wins Gold at the PwC Sustainability Impact Awards
From Advanced Semiconductor Engineering, Inc.
Via Business Wire
News headline image
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial 
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cogstate Expands Alzheimer's Disease Leadership with Appointment of Dr. Kaycee Sink, as Chief Medical Officer
From Cogstate Ltd.
Via GlobeNewswire
News headline image
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.